August 22, 2019
In light of a recent Federal Circuit decision, Amgen Inc. can no longer allege that Mylan Inc.'s proposed Neulasta biosimilar infringed one of its patents, a Pennsylvania federal court ruled Wednesday, granting a joint request from both parties to nix the claim.
April 09, 2018
Mylan Inc.'s proposed Neulasta biosimilar doesn't use the salt pairs covered in a patent Amgen Inc. is accusing it of infringing, Mylan told a Pennsylvania federal court Friday, hoping to get the claim killed by relying on an argument that got a similar suit over the patent dismissed last month.
September 25, 2017
Mylan Inc. infringed two of Amgen Inc.'s patents when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patents expired, the biologic maker told a Pennsylvania federal court Friday.